A boxed warning has been added to the label for Estradiol and Norethindrone Acetate, effective 2026-06-26. This significant label revision highlights potential serious risks, including cardiovascular disorders, probable dementia, breast cancer, and endometrial cancer. The presence of a boxed warning indicates that the FDA has identified serious or life-threatening adverse effects associated with the drug's use.
Background
The label for Estradiol and Norethindrone Acetate now includes a prominent boxed warning, drawing attention to critical safety information. This warning specifically details risks such as cardiovascular disorders, the potential for probable dementia, and an increased incidence of certain malignancies, namely breast cancer and endometrial cancer. Such warnings are implemented to ensure that healthcare professionals and patients are fully aware of the most severe potential side effects and contraindications associated with a medication.
What this means
The addition of a boxed warning to the label for Estradiol and Norethindrone Acetate on 2026-06-26 represents a crucial update in the safety profile of the medication. Boxed warnings are the strongest cautionary statements mandated by the FDA, indicating that the drug carries significant risks that may lead to serious injury or death. For healthcare providers, this update necessitates a thorough review of patient medical history and risk factors related to cardiovascular disorders, probable dementia, breast cancer, and endometrial cancer before prescribing. Patients should also be fully informed about these potential serious adverse events to make informed decisions regarding their treatment, ensuring a comprehensive understanding of the benefits and risks involved.
Source
This label revision was issued by the FDA, effective 2026-06-26. The full prescribing information detailing the boxed warning is available on dailymed.nlm.nih.gov, an official database of drug labeling information provided by the National Library of Medicine.